|Bid||12.56 x 83900|
|Ask||12.57 x 30000|
|Day's range||12.29 - 12.58|
|52-week range||7.84 - 12.58|
|PE ratio (TTM)||60.72|
|Forward dividend & yield||0.16 (2.94%)|
|1y target est||8.30|
Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) may face issues if the North American Free Trade Agreement is re-negotiated.
Fisher & Paykel Healthcare has won a patent case against rival medical products manufacturer ResMed, after a court in the United Kingdom ruled the patent claim invalid. In 2016, New Zealand-based Fisher & Paykel sought a declaration from the High Court that three of ResMed's European patents were invalid in the UK and should be revoked. ResMed revoked two of its patents in the UK just before the trial was due to start, but left one for consideration by the High Court's patents division.